The Filing Desk

Mesa Laboratories

MLAB · Nasdaq · Health Care · Financials, fiscal 2017 to 2026

MLAB · Last close · November 13, 2026
$139.01
Value Mesa Laboratories yourself

Mesa Laboratories' revenue rose 3.4% to $249 million in fiscal 2026. Its operating margin was 7.4%, up from 6.8% a year earlier. Free cash flow was $40 million, down 7.0%. It paid out $4 million in dividends and buybacks, 9% of free cash flow. The diluted share count rose 2.7%.

MESA LABORATORIES INC /CO Latest fiscal year ended March 31, 2026 10-K filed June 3, 2026 · 0000724004-26-000047 Updated
Revenue
$249M
3.4%
Operating margin
7.4%
0.6 pts
Net income
$7M
 
Free cash flow
$40M
7.0%
Return on capital
4.8%
1.5 pts
Market cap
$806M
Nov 13 close
P/E
120.9x
On $1.15 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Mesa Laboratories does

Mesa Laboratories, based in Lakewood, Colorado, makes tools and quality control products for pharmaceutical, healthcare and medical device companies. Customers use them to check that their processes work, for example that sterilization really killed germs. Mesa makes its products in the United States and Europe and sells them through its own sales staff in North America, Europe and Asia Pacific, and through independent distributors worldwide. Its fiscal year ends on March 31.

It reports four segments. Sterilization and Disinfection Control makes biological, chemical and cleaning indicators that show whether sterilization and cleaning worked, mostly single-use items, and offers testing services to dental and drug customers. Biopharmaceutical Development makes automated protein-testing systems and equipment for making peptides, which are short chains of amino acids. Calibration Solutions makes instruments for measuring and calibrating things like gas flow and torque. Clinical Genomics makes genetic analysis instruments and consumables for research labs.

Mesa earns money by selling products, mostly consumables and hardware, and services such as maintenance, calibration and testing. It grows by selling more to current customers and by buying other companies that fit its range. In fiscal 2026 its Clinical Genomics sales fell because of weak demand in China and trade tensions, and Mesa expects that to continue into fiscal 2027.

Its biggest risks, as it describes them

  • Weak conditions in the economy and in the markets it serves, including weak demand and trade tensions in China.
  • Competition from a wide range of rivals, and industry consolidation or shifts in customer behavior.
  • Relying on distributors and other channel partners to reach customers.
  • Needing to develop new products on time and win customer acceptance for them.
  • Problems getting materials, components and labor on time, and managing growth from acquisitions.
From Mesa Laboratories's annual report on Form 10-K, filed June 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2026, earnings per share fell 9.3% a year and net income 5.5% a year, as new shares raised the share count by 47% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments4933282727
Debt incl. finance leases1691701717168
Net debt (negative means net cash)1201371434441
Net debt to EBITDA4.0x3.7x—1.1x1.0x
Debt to equity0.4x0.4x1.2x0.5x0.4x
Interest coverage1.2x0.7x−47.8x1.4x1.7x
Current ratio2.6x2.7x2.5x0.6x1.7x
Quick ratio2.1x1.9x1.7x0.5x1.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Mesa Laboratories' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Mesa Laboratories says to expect

  • Fiscal year 2027: revenues and adjusted EBITDAIssued full-year fiscal 2027 guidance for the first time: revenues of $250,000 to $255,000 and adjusted EBITDA of $66,000 to $68,000
  • Third quarter fiscal 2027: revenuesThird quarter revenues are expected to be about flat compared with the prior-year period, mainly because of lower Clinical Genomics revenues.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Mesa Laboratories reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score4 of 96 of 98 of 9
Rule of 4017.9%29.1%19.3%
Altman Z''−3.97−1.480.37
Accruals ratio−53.8%−11.1%−8.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positiveFailFailPass
Cash from operations is positivePassPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score4 of 96 of 98 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Mesa Laboratories side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Mesa LaboratoriesFY263.4%7.4%15.9%4.8%1.0x8
Cytek BiosciencesFY250.5%−20.0%−4.3%———Compare
Maravai LifeSciencesFY25−28.3%−115.9%−38.1%−32.0%—2Compare
CryoportFY2512.4%−20.9%−14.2%−23.4%—4Compare
Ginkgo BioworksFY25−25.1%−185.3%−105.0%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue9496103118134184219216241249
Revenue growth10.6%2.7%7.2%14.1%13.8%37.6%18.9%−1.3%11.5%3.4%
Gross profit5355616587109134133151158
Research and development4446101620192020
Operating income1621081253−2721618
Net income11−382321−254−27
Diluted EPS (US$)2.91−0.791.860.410.640.350.17−47.20−0.361.21
Diluted shares (millions)4444555556
Cash flow
Cash from operations17263127373928444743
Capital expenditure—312244343
Free cash flow—232925353523424340
Dividends paid2223333344
Share buybacks0000000000
Acquisitions9165184030157900
Stock-based compensation124691112121318
Balance sheet at fiscal year end
Cash and short-term investments6610812644933282727
Debt incl. finance leases5546,62523—1461691701717168
Total assets172164157409602707662447433428
Total liabilities746546189195314268301274242
Shareholders' equity9899111220406394394145160186
Margins and ratios
Gross margin56.8%56.8%59.1%55.5%65.0%59.2%61.0%61.6%62.6%63.5%
Operating margin17.4%2.3%9.5%6.7%9.2%2.5%1.5%−125.8%6.8%7.4%
Net margin11.9%−3.1%7.3%1.5%2.4%1.0%0.4%−117.6%−0.8%2.7%
Free cash flow margin—23.8%28.4%21.7%26.2%18.9%10.7%19.2%17.7%15.9%
Rule of 40 (growth + FCF margin)—26.5%35.6%35.8%40.0%56.5%29.6%17.9%29.1%19.3%
Return on capital9.4%0.0%0.0%——0.6%0.5%−52.5%3.3%4.8%
Return on equity12.3%−3.0%7.1%1.1%1.1%0.5%0.2%−94.4%−1.3%3.9%
Return on assets6.7%−1.8%4.7%0.6%0.7%0.3%0.1%−45.9%−0.5%1.6%
Net debt to EBITDA2.0x4,000.3x0.7x—−3.9x4.0x3.7x—1.1x1.0x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Mesa Laboratories' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Mesa Laboratories.